Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for liver transplantation: A systematic review

Liver Transplantation

Volumn 13, Issue 8, 2007, Pages 1125-1136

  Feng, Li ^a   Zhao, Na ^b   Yao, Xun ^a,b   Sun, Xin ^b   Du, Liang ^b   Diao, Xiang ^b   Li, Shengfu ^a   Li, Youping ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b Chinese Evidence Based Medicine/Cochrane Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; HTK SOLUTION; PRESERVATION SOLUTION; UNIVERSITY OF WISCONSIN SOLUTION;

BILE DUCT DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; FOLLOW UP; GOLD STANDARD; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; INTERMETHOD COMPARISON; LIVER GRAFT REJECTION; LIVER PRESERVATION; LIVER TRANSPLANTATION; LIVING DONOR; MEDICAL DOCUMENTATION; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADENOSINE; ALLOPURINOL; ANIMALS; CLINICAL TRIALS; COHORT STUDIES; GLUCOSE; GLUTATHIONE; HUMANS; INSULIN; LIVER; LIVER TRANSPLANTATION; MANNITOL; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; PERFUSION; POTASSIUM CHLORIDE; PROCAINE; RAFFINOSE; TREATMENT OUTCOME;

EID: 34548163309     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21208     Document Type: Review

References (42)

1. Belzer FO, Southard JH. Principles of solid organ preservation by cold storage. Transplantation 1988;45:673-676.
2. Azoulay D, Linhares MM, Huguet E, Delvart V, Castaing D, Adam R, et al. Decision for retransplantation of the liver: an experience and cost-based analysis. Ann Surg 2002; 236:713-721.
3. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4000 consecutive patients at a single center. Ann Surg 2000;232:490-500.
4. Jimenez M, Turrion VS, Alvira LG, Lucena JL, Ardaiz J. Indications and results of retransplantation after a series of 406 consecutive liver transplantations. Transplant Proc 2002;34:262-263.
5. Deshpande RR, Rela M, Girlanda R, Bowles MJ, Muiesan P, Dhawan A, et al. Long-term outcome of liver retransplantation in children. Transplantation 2002;74:1124-1130.
6. Jain A, Mazariegos G, Kashyap R, Kosmach-Park B, Starzl TE, Fung JJ, et al. Pediatric liver transplantation in 808 consecutive children: 20-years experience from a single center. Transplant Proc 2002;34:1955-1957.
7. OH CK, Sawyer RG, Pelletier SJ, Pruett TL, Sanfey HA. Independent predictors for primary non-function after liver transplantation. Yonsei Med J 2004;45:1155-1161.
8. Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 2004;10:434-439.
9. Cavallari A, Cillo U, Nardo B, Filipponi F, Gringeri E, Montalti R, et al. A multicenter pilot prospective study comparing celsior and University of Wisconsin preserving solutions for use in liver transplantation. Liver Transpl 2003; 9:814-821.
10. Canelo R, Hakim NS, Ringe B. Expeience with histidine tryptophan ketoglutarate versus University Wisconsin preservation solutions in transplantation. Int Surg 2003; 88:145-151.
11. Blankensteijn JD, Terpstra OT. Liver preservation: the past and the future. Hepatology 1991;13:1235-1250.
12. Muhlbacher F, Langer F, Mittermayer C. Preservation solutions for transplantation. Transplant Proc 1999;31: 2069-2070.
13. Ringe B, Braun F, Moritz M, Zeldin G, Soriano H, Meyers W. Safety and Efficacy of Living Donor Liver Preservation With HTK Solution. Transplant Proc 2005;37:316-319.
14. Erhard J, Lange R, Scherer R, Kox WJ, Bretschneider HJ, Gebhard MM, et al. Comparison of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation: a prospective, randomized study. Transpl Int 1994;7:177-181.
15. Lange R, Erhard J, Rauen U, de Groot H, Eigler FW, Hepatocellular injury during preservation of human livers with UW and HTK solution. Transplant Proc 1997;29:400-402.
16. Moench C, Otto G. Ischemic type biliary lesions in histidine-tryptophan-ketoglutarate (HTK) preserved liver grafts, Int J Artif Organs 2006;29:329-334.
17. Avolio AW, Agnes S, Nure E, Maria G, Barbarino R, Pepe G, et al. Comparative evaluation of two perfusion solutions for liver preservation and transplantation. Transplant Proc 2006;38:1066-1067.
18. Mangus RS, Tector AJ, Agarwal A, Vianna R, Murdock P, Fridell JA. Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in adult liver transplantation. Liver Transpl 2006;12: 226-230.
19. Hatano E, Kiuchi T, Tanaka A, Shinohara H, Kitai T, Satoh S, et al. Hepatic preservation with histidine-tryptophan-ketoglutarate solution in living-related and cadaveric liver transplantation. Clin Sci 1997;93:81-88.
20. Kinoshita K, Ikai I, Gomi T, Kanai M, Tsuyuki S, Hirose T, et al. Exposure of hepatic sinusoidal mononuclear cells to UW solution but not induces apoptosis. J Hepatol 1998; 29:300-305.
21. Testa G, Malago M, Nadalin S, Treptow B, Paul A, Frilling A, et al. Histidine-tryptophan-ketoglutarate versus University of Wisconsin solution in living donor liver transplantation: results of a prospective study. Liver Transpl 2003;9:822-866.
22. Chan SC, Liu CL, LO CM, Fan ST. Applicability of Histidine-Tryptophan-Ketoglutarate solution in right lobe adult-to-adult live donor liver transplantation. Liver Transpl 2004;10:1415-1421.
23. Center for Evidence-Based Medicine. 2005. Available at: http://www.cebm.net/index.aspx?o=1025. Accessed May 17, 2006.
24. Chui AKK, Shi LW, Rao ARN, Anasuya A, Hagl C, Pillay P, et al. Primary graft dysfunction after liver transplantation. Transplant Proc 2000;32:2219-2220.
25. Brokelman W, Stel AL, Ploeg RJ. Risk factors for primary dysfunction after liver transplantation in the University of Wisconsin Solution era. Transplant Proc 1999;31:2087-2090.
26. Fernandez-Merino J, Nuno-Garza J, Lopez-Hervas P, Lopez-Buenadicha A, Quijano-Collazo Y, Vicente-Lopez E. Influence of ischemia and surgery times on development of primary dysfunction liver transplant in patients. Transplant Proc 2003;35:1439-1441.
27. Bretschneider HJ. Myocardial protection. Thorac Cardiovasc Surg 1980;28:295-302.
28. Upadhya GA, Strasberg SM. Glutatione, lactobionate, and histidine cryptic inhibitors of matrix metalloproteinase container in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions. Hepatology 2000;31:1115-1122.
29. Sotil EU, Koffron A, Abecassis M. Comparison of HTK to UW solution in living donor liver transplantation [abstract]. Am J Transplant 2006;6(Suppl):917.
30. Tullius S, Filatenkow A, Horch D, Mehlitz T, Selke AR, Pratschke J, et al. Accumulation of crystal deposits in abdominal organs following perfusion with defrosted University of Wisconsin solution. Am J Transplant 2002;2: 627-630.
31. Welling TH, Heidt D, Englesbe MJ, Magee JC, Sung RS, Campbell DA, et al. Risk factors for biliary strictures following liver transplantation during the meld era: effect of donor, recipient, and preservation variables [abstract]. Am J Transplant 2006;6(Suppl):726.
32. Moray G, Sevmis S, Karakayali F, Gorur S, Haberal M. Comparison of Histidine-Tryptophan-Ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in living-donor liver transplantation [abstract]. Am J Transplant 2006;6(Suppl):204.
33. Martinez JA, Guerra J, Jarufe N, Pacheco F, Soza A, Gonzalez R, et al. Histidine-Tryptophan-Ketoglutarate (HTK) solution is clinically equivalent but less expensive than the University of Wisconsin (UW) solution for cadaveric liver transplantation. A prospective study [abstract]. Am J Transplant 2006;6(Suppl):202.
34. Janssen H, Janssen PH, Broelsch CE. UW is superior to Celsior and HTK in the protection of human liver endothelial cells against preservation injury. Liver Transpl 2004; 10:1514-1523.
35. Abrahamse SL, van Runnard Heimel P, Hartman RJ, Chamuleau RA, van Gulik TM. Induction of necrosis and DNA fragmentation during hypothermic preservation of hepatocytes in UW, HTK, and Celsior solutions. Cell Transplant 2003;12:59-68.
36. Straatsburg IH, Abrahamse SL, Song SW, Hartman RJ, Van Gulik TM. Evaluation of rat liver apoptotic and necrotic cell death after cold storage using UW, HTK, and Celsior. Transplantation 2002;74:458-464.
37. Walcher F, Marzi I, Buhren V. The impact of liver preservation in HTK and UW solution on microcirculation after liver transplantation. Transpl Int 1992;(5 Suppl 1):s340-s342.
38. Moench C, Moench K, Lohse AW, Thies J, Otto G. Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion. Liver Transpl 2003;9:285-289.
39. Noack K, Bronk SF, Kato A, Gores GJ. The greater vulnerability of bile duct cells to reoxygenation injury than to anoxia. Implications for the pathogenesis of biliary strictures after liver transplantation. Transplantation 1993; 56:495-500,
40. Olschewski P, Hunold G, Winkler R, Schöning W, Schmitz V, Eipel C, et al. Initial graft flush using HTK improves subsequent storage in UW solution - two step study using isolated rat liver reperfusion and transplantation model [abstract], Am J Transplant 2006;6(Suppl):915.
41. Pirenne J, Van Gelder F, Coosemans W, Aerts R, Gunson B, Koshiba T. Type of donor aortic preservation solution and not cold ischemia time is a major determinant of biliary strictures after liver transplantation. Liver Transpl 2001;7:540-545.
42. Adam R, Astarcioglu I, Raccuia JS, Ducot B, Reynes M, Bismuth H. Beneficial effects of Eurocollins as aortic flush for the procurement of human livers. Transplantation 1996;61:705-709.